The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease
Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, Zhang J, Sun C, Zhang Y, Ju X
European neurology · 48 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2015-01-01 · Eur Neurol · vol. 73 · issue 3-4 · pp. 205–211
- Publisher
- Karger Publishers
- Cited
- 76 citations · more than 90% of similar papers · 2.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 31 works
- Access
- Paywalled
- Research areas
- Coenzyme Q10 studies and effects · Parkinson's Disease Mechanisms and Treatments · Biochemical effects in animals
- Keywords
- Coenzyme Q10, Montreal Cognitive Assessment, Internal medicine, Medicine, Creatine, Parkinson's disease, Combination therapy, Placebo, Gastroenterology, Physical therapy, Disease, Cognitive impairment, Pathology
- MeSH
- humans, parkinson disease, creatine, ubiquinone, drug therapy, combination, cognition, aged, middle aged, female, male, cognitive dysfunction
10 authors
From CN
- Zhenguang LiBinzhou Medical University; Weihai Municipal Hospital
- Pengfei WangBinzhou Medical University; Weihai Municipal Hospital
- Zhancai YuBinzhou Medical University; Weihai Municipal Hospital
- Yannan CongBinzhou Medical University; Weihai Municipal Hospital
- Hairong SunBinzhou Medical University; Weihai Municipal Hospital
- Jiangshan ZhangBinzhou Medical University; Weihai Municipal Hospital
Abstract
Background
To investigate the effect of creatine and coenzyme Q10 (CoQ10) combination therapy on mild cognitive impairment (MCI) in Parkinson's disease (PD; PD-MCI) and its influences on plasma phospholipid (PL) levels in PD-MCI.
Methods
The demographic data of 75 PD-MCI patients who enrolled in this collaborative PD study were collected. These patients were evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) III and the Montreal Cognitive Assessment (MoCA). These 75 PD-MCI patients were randomly treated with creatine monohydrate 5 g b.i.d. and CoQ10 100 mg t.i.d. orally or placebo. MoCA evaluation and PL level measurements were performed after 12 and 18 months of treatment.
Results
After 12 and 18 months of treatment, the differences in the MoCA scores of the combination therapy and control groups were statistically significant (p < 0.05 at 12 months and p < 0.01 at 18 months), and the plasma PL levels of the combination therapy group were significantly lower than those of the control group (p < 0.01 at 12 months and p < 0.001 at 18 months).
Conclusions
Combination therapy with creatine and CoQ10 could delay the decline of cognitive function in PD-MCI patients and could lower their plasma PL levels; therefore, this combination therapy may have a neuroprotective function.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.